TriangleNCT03146871 · OUTCOME
Time to Death From Any Cause
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Months
- Interval / dispersion
- Full Range
- Time frame
- up to 1 year (12 cycles)
What was measured
Will be displayed with Kaplan-Meier plots.
Groups in this outcome
Treatment (sEphB4-HSA, Azacitidine, Decitabine)
Patients receive recombinant EphB4-HSA fusion protein intravenously (IV) over 60 minutes on days 1 and 15. Patients also receive azacitidine IV or subcutaneously (SC) on days 1-7 or days 1-5 and 8-9, or decitabine IV on days 1-5. Administration of recombinant EphB4-HSA fusion protein occurs before or after the HMA (not concurrently). Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Azacitidine: Given IV or SC Decitabine: Given IV Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Recombinant EphB4-HSA Fusion Protein: Given IV
| Group | Source count |
|---|---|
| Treatment (sEphB4-HSA, Azacitidine, Decitabine) | 7 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Treatment (sEphB4-HSA, Azacitidine, Decitabine) | 4.1 | Not reported | 2.9 | 22.0 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 2.9
- upper Limit
- 22.0
- value
- 4.1
- denoms
- counts
- group Id
- OG000
- value
- 7
- units
- Participants
- description
- Will be displayed with Kaplan-Meier plots.
- dispersion Type
- Full Range
- groups
- description
- Patients receive recombinant EphB4-HSA fusion protein intravenously (IV) over 60 minutes on days 1 and 15. Patients also receive azacitidine IV or subcutaneously (SC) on days 1-7 or days 1-5 and 8-9, or decitabine IV on days 1-5. Administration of recombinant EphB4-HSA fusion protein occurs before or after the HMA (not concurrently). Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Azacitidine: Given IV or SC Decitabine: Given IV Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Recombinant EphB4-HSA Fusion Protein: Given IV
- id
- OG000
- title
- Treatment (sEphB4-HSA, Azacitidine, Decitabine)
- param Type
- MEDIAN
- reporting Status
- POSTED
- time Frame
- up to 1 year (12 cycles)
- title
- Time to Death From Any Cause
- type
- PRIMARY
- unit Of Measure
- Months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice